Israeli medical device firm Allium Medical has submitted an application to US Food and Drug Administration (FDA) seeking clearance for the Wirion filter system, which is designed to protect from emboli released during catheterisation procedures.

Allium Medical said the FDA indication is for use of the Wirion system during carotid catheterisation procedures.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The application was submitted in the 510(k) regulatory track based on interim clinical data, which showed the system safety profile was significantly better compared to the control group.

The company started enrolling 120 additional patients in the clinical trial under study protocol.

Allium Medical CEO Asaf Alperovitz said: "We are taking another step towards FDA clearance for marketing the Gardia unique filter in the US.

See Also:

"The application was submitted in the 510(k) regulatory track based on interim clinical data, which showed the system safety profile was significantly better compared to the control group."

"The application is based on the interim clinical results that include data from 120 out of the planned 240 patients and demonstrate that the safety profile (the primary end-point of the study) is significantly better compared to the control group (that includes data from cleared US products of global companies."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Under trial protocol, to meet the primary end-point at this early stage, the company has to meet strict statistical criteria compared to statistical criteria for the full group trial.

According to the statistical method shown in trial protocol, the company did not meet the interim primary end-point that would allow the trial to end at interim.

However, according to the alternative exact binomial statistical method, the company met the trial endpoint at interim stage.

In correspondence between Allium Medical and the FDA, it was stated the alternative exact binomial method proposed by the company will be considered by the FDA following review of the totality of full submission data.

The FDA is expected to respond to the application within 90 days of receiving confirmation that all administrative conditions for the application were met.